Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
about
Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationPhase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsHematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.Current clinical indications for plerixaforPlerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies.Hematopoietic stem cell mobilization: current status and future perspective.Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.How do we mobilize and collect autologous peripheral blood stem cells?Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation.Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.Plerixafor: what we still have to learn.Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
P2860
Q26825518-07BECA02-A56F-4FA8-BF67-26711CB317D7Q33411277-44D8317A-7013-428C-B426-2EACEDDD4A0FQ34454624-8B01F702-8321-46AD-B66E-2DC3956E8848Q36428104-0057ED8B-7C04-48E5-BA72-922FB6F96C9FQ38176669-FCDACAE6-4DCC-4CC7-B95F-7DF3D46C6181Q38177784-BD7C94E6-5A8C-404F-A1BF-E91E363AF96CQ38199707-653AF0A3-EB54-4CAB-AA8D-42052AA33073Q38200909-54708FE9-06F9-4CEB-B7B8-7887141B6592Q38256923-DB4553D4-8A24-4605-B8C2-EFE23A0C24EFQ38658893-ECD728EF-5181-4FD1-BAEE-CCC905873805Q38771080-113631B6-CF2A-40E6-8C85-E967C186E732Q38880504-6698154E-C4E4-4E4C-BCEB-107FEAB27DE5Q38978669-014E0AB9-0E5E-44FB-92B0-8B6927505A74Q40490106-8DA9F8C6-3238-4DF2-BE92-5B2CD5055147Q41267193-316B49FA-E96E-4D95-93EC-B22D19030034Q41694417-857AC8AA-C23C-4A69-B13D-88AAEC13C80DQ43563982-3C6626C1-6CF9-4D40-8275-E3C1517EDD74Q44256421-0E1EFFB8-0714-4881-BC43-95C133D74254Q44986060-FA5ADA36-555B-4002-B850-BA80B35D00C7Q46047228-52EB5D52-DC38-4197-8C7C-7BBA5E4B9F19Q46654811-455CC098-0F02-473A-9810-CF826B0B539FQ46877033-3D15A272-F739-46EF-88E7-B5F7E36BC722Q47263519-C3AE2F88-13B4-4F11-B7C0-B63B09EFB676Q47914097-B16B4B20-811E-48B7-805C-34EF8C2247F2Q48097743-41C9C529-82F7-4B4E-8D20-1506C1DA6F7FQ48251589-F0B6BCE4-8AFF-4BF5-A064-931B300F4373Q48337454-398DAB64-AB34-4FA5-BBE4-43FE0C97DB8EQ48747463-37856BC8-7055-47DA-A76C-F5A6F6262A89Q50690379-B1BB2279-E2A9-426E-AD02-B48C43283373Q51776428-3984FCE8-9D07-4D12-8691-46E3B189C413
P2860
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@en
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@nl
type
label
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@en
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@nl
prefLabel
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@en
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@nl
P2093
P50
P1476
Cost-effectiveness analysis of ...... blood stem cell mobilization.
@en
P2093
David J Inwards
Dennis A Gastineau
Francis Buadi
Ivana N M Micallef
Luis F Porrata
Mark R Litzow
Patrick B Johnston
Robert Wolf
Shaji Kumar
Shirshendu Sinha
P356
10.1016/J.BBMT.2012.08.010
P577
2012-08-23T00:00:00Z